Cytotoxicity and exhaustion markers of chimeric antigen receptor T cells targeting BCMA in multiple myeloma cell lines between patients and healthy donors
Issued Date
2023-01-01
Resource Type
ISSN
09024441
eISSN
16000609
Scopus ID
2-s2.0-85160104805
Pubmed ID
37222081
Journal Title
European Journal of Haematology
Rights Holder(s)
SCOPUS
Bibliographic Citation
European Journal of Haematology (2023)
Suggested Citation
Prasongtanakij S., Preedagasamzin S., Jittorntrum B., Anurathapan U., Puavilai T., Niparuck P., Chantrathammachart P., Piyajaroenkij T., Uaesoontrachoon K., Uchibori R., Ozawa K., Ohmine K., Hongeng S. Cytotoxicity and exhaustion markers of chimeric antigen receptor T cells targeting BCMA in multiple myeloma cell lines between patients and healthy donors. European Journal of Haematology (2023). doi:10.1111/ejh.14007 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82916
Title
Cytotoxicity and exhaustion markers of chimeric antigen receptor T cells targeting BCMA in multiple myeloma cell lines between patients and healthy donors
Author's Affiliation
Other Contributor(s)
Abstract
Objectives: Multiple myeloma (MM) accounts for 10% of hematologic malignancies. However, most of the patients suffered from relapsed/refractory disease. We would like to expand CAR T cell therapy to treat MM using our current platform. Methods: BCMA CAR T lymphocytes were generated for volunteers or MM patients. The transduction efficiency was detected by the ddPCR technique. Immunophenotyping and exhaustion markers were monitored by flow cytometry. The efficacy of BCMA CAR T cells was tested using coculturing with BCMA CAR or mock, and the positive and negative targets, K562/hBCMA-ECTM and K562, respectively. Results: BCMA CAR T cells were generated from consented volunteers or MM patients and could be detected CAR BCMA expression at a mean of 4.07 ± 1.95 or 4.65 ± 1.21 copies/cell, respectively. Those modified T cells were primarily effector memory T cells. Our BCMA CAR T cells could explicitly eradicate the K562/hBCMA-ECTM cell line while the K562 cell line survived. Interestingly, the BCMA CAR, mock T cells, and peripheral blood mononuclear cells from MM patients expressed similar levels of the exhaustion makers, TIM-3, LAG-3, and PD1. Conclusions: Our BCMA CAR T cells, mainly effector/effector memory, could eliminate BCMA-expressing cells in vitro and had similar levels of exhaustion markers among different populations.